ClinicalTrials.gg
RecruitingNCT06423716RELIFEUpdated Aug 12, 2026

Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)

A Phase 4 interventional study of Duloxetine and Placebo in Knee Osteoarthritis, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 2 sites in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Sunnybrook Health Sciences Centre · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing duloxetine in Osteoarthritis, Knee — 4 open to participants now, 4 under way, none of them phase 3. duloxetine · Osteoarthritis, Knee.

Planned enrollment
8th of 19
150 · median 102
Started
2024
with 1 other
Phase 4
6 of 19
3 open now
Registered
17th of 19
by date

Among the 19 studies testing duloxetine in Osteoarthritis, Knee, this one is the 8th largest by planned enrollment, is one of 2 that started in 2024, is one of 6 in phase 4, and was the 17th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

4 of the 19 studies testing duloxetine in Osteoarthritis, Knee are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About duloxetine

duloxetine: first FDA approval 2004 (CYMBALTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing duloxetine in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

Knee replacement surgery for osteoarthritis is a commonly performed procedure in Canada with 75,000 of these surgeries performed each year. Success rate for knee replacement surgery is high but more than 20% of patients are still dissatisfied mainly due to reports of ongoing pain. Pain control following knee surgery is important in order to allow patients to engage in recovery and rehabilitation. The current standard of pain management after surgery centers around the use of opioids which is a concerning practice as highlighted by the opioid epidemic. Duloxetine is an antidepressant that has pain relieving properties and it has been studied in patients undergoing knee replacement surgery. Studies to date have not been designed optimally to demonstrate the full effects of opioid dose reduction and the use of duloxetine as a medication following knee replacement surgery. This research study seeks to start duloxetine before surgery, at the recommended therapeutic dose, and for the duration of the early rehabilitation period. If the study is successful, this low-cost medication can improve satisfaction rates and change the standard way the pain management is typically carried out for patients undergoing the knee replacement surgery.

Read the detailed description

The use of duloxetine around the time of total knee arthroplasty has emerged as a promising intervention to help with pain management after surgery and in particular as an opioid sparing agent. Duloxetine is an antidepressant with serotonin and norepinephrine reuptake inhibition effects that also independently exerts an analgesic effect. Duloxetine is Health Canada approved for several indications including pain arising from osteoarthritis of the knee. Pain inhibition action of duloxetine is believed to be a result of potentiation of descending inhibitory pain pathways within the central nervous system. Existing studies examining duloxetine use at the time of surgery has demonstrated statistically significant but less clinically meaningful impacts on opioid sparing and pain reduction. The deficiencies in study design of existing studies have either underdosed duloxetine (30mg instead of the recommended 60mg) and/or utilized non-standard duration of therapy (started too late, continued for only 2 weeks). This study seeks to definitively address whether duloxetine administered 2 weeks preoperatively at 60mg once daily, in addition to standard analgesic practice, will decrease opioid consumption at 1 week postoperatively.

Prospective, randomized, blinded (investigators, clinicians, participant, data collectors/analysts) trial.

Primary Outcome

•Cumulative opioid consumption at 1 week post-operatively.

Secondary Outcomes

  • Nausea/vomiting
  • Discharged according to plan (ie. same day went home same day, or day 1 went home day 1) and if not, reason
  • Pain at rest and with activity (NRS-11) at 1, 6, and 12 weeks and 4.5 months
  • Additional analgesic use (anti-neuropathic medications, family physician or orthopaedic surgeon opioid prescription)
  • Physical function (BPI, Oxford Knee Scale, range of motion
  • Emotional function (GAD-7, PHQ-9 at 6 weeks and 12 weeks)
  • Number of rehabilitation sessions attended (in-person or virtual)
  • Patient satisfaction (PGIC) at 1, 6, and 12 weeks after medication initiation
  • Presence of neuropathic pain (S-LANSS) at 6 and 12 weeks
  • Presence of chronic post-surgical pain at 12 weeks (based on NRS > 0)
  • Adverse events relating to study medication (dizziness, drowsiness, nausea, vomiting, insomnia)
  • Intervention adherence

Interventional medication supply: Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.

Standard of care: On the day of surgery, participants will be premedicated with acetaminophen (1000mg) and celecoxib (400mg). Per standard of care, all participants will receive an ultrasound guided adductor canal catheter (bolus ropivacaine 0.5% 10ml). This will be followed by a spinal anesthetic with mepivacaine 2% 3ml and 10mcg of fentanyl. Intraoperative sedation will consist of a propofol infusion titrated to SAS (Sedation Agitation Scale) of 3-4.

All TKAs will be performed using a standard medial parapatellar approach and the same cemented total knee system. Tourniquet will be applied and used as part of the case. Periarticular local infiltration will be used per standard practice using ropivacaine 0.2% with 1:200 000 epinephrine up to 50ml.

Post-surgery: Participants will be evaluated on POD-0, POD-1 and POD-2 while in hospital or at home through phone call and at 1, 6, and 12 weeks.

Participant satisfaction will be assessed using the Patients' Global Impression of Change (PGIC) Scale at 1, 6, and 12 weeks post-surgery.

Pain scores and opioid consumption will be recorded daily for 1 week post-operatively.

Patients will record their pain and opioid consumption on a weekly basis until week 12 post-operatively.

Physical function, emotional function, and presence of neuropathic pain will be collected at 6 and 12 weeks.

Active and passive range of motion will be assessed by orthopedic surgeon using goniometer at 6 (+/-1 week) and 12 (+/-1 week) weeks and 4.5 month (+/-2 weeks) postoperatively.

Group 1: Intervention Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.

Group 2: Control Placebo OD for 2 weeks preoperatively then OD for 6 weeks post-surgery.

Both Groups:

On the day of surgery, standard post-anesthetic care unit (PACU) orderset will be employed and the postoperative analgesic regimen will follow standard of care including: acetaminophen 1g QID, celecoxib 200mg BID, and hydromorphone 1-3mg PO q2h PRN.

  • Nurse administered IV hydromorphone push (0.3mg) followed by IV PCA hydromorphone if pain is not controlled
  • ACB catheter ropivacaine 0.15% at 5cc/hr, stopped at 6:00am on POD-1

Participants will be discharged on POD-0, POD-1 or POD-2 with acetaminophen 1000mg TID, celecoxib 100mg BID, and hydromorphone (2-4mg PO q4h PRN). Patients for same-day discharge (POD-0) will have ACB catheter bolus of 10cc of 0.5% ropivacaine prior to removal.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • total knee arthroplasty
  • duloxetine
  • postoperative pain
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >=50
  2. Presence of knee osteoarthritis
  3. Planned for elective unilateral total knee arthroplasty
  4. Baseline (CrCl) ≥ 30 mL/min within 60 days prior to enrolment, if available. If not available, verbal report from patient of no known renal disease.

Exclusion criteria

Exclusion Criteria:

  1. Lack of patient consent; unlikely to comply with follow-up
  2. Presence of to study drug use:

    • Known to the drug or components of the product
    • Known liver disease - history of cirrhosis, non-alcoholic steatohepatitis
    • Uncontrolled narrow - angle glaucoma
    • Severe renal impairment (\<30mL/min)
    • Concurrent use of thioridazine
    • Concurrent use of potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin)
    • Concurrent use of antidepressants (e.g. MAOI, SSRI, SNRI, TCA, St. John's Wort, buspirone)
    • Concurrent use of triptan or lithium
  3. Chronic and high dose opioid use (>30mg oral morphine equivalent per day)
  4. Substance use disorder (cannabis and related products, alcohol use disorder, opioid used disorder, illicit drugs)
  5. Uncontrolled hypertension (systolic BP > 180mmHg)
  6. Untreated psychiatric illness (e.g. depression, suicidal ideation, bipolar disorder)
  7. Involved in worker's compensation case/law suit (verbally declared by patient)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Intervention

    Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.

    Drug: Duloxetine

  • Placebo comparator
    Control

    Placebo OD for 2 weeks preoperatively then OD for 6 weeks post-surgery.

    Drug: Placebo

Interventions

  • 60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.

  • DrugPlacebo

    Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.

06

What researchers measure

Primary outcomes

  1. Opioid consumption

    Cumulative opioid consumption at 1 week post-operatively

    Time frame: Cumulative opioid consumption at 1 week post-operatively

Secondary outcomes

  1. Nausea/vomiting

    Presence of nausea or vomiting

    Time frame: 12 weeks (i.e., duration of study)

  2. Pain at rest and with activity

    Maximum pain score on 0-10 Likert Scale (NRS)

    Time frame: 10-14 days preoperative; 1,6,12 weeks and 4.5 months

  3. Additional analgesic use

    Anti-neuropathic medications

    Time frame: 8 weeks (i.e., duration of study)

  4. Additional analgesic use: opioid prescription

    Family physician or orthopaedic surgeon opioid prescription

    Time frame: 8 weeks (i.e., duration of study)

  5. Physical function measured by BPI

    Brief Pain Inventory

    Time frame: Preoperative, 6, 12 weeks and 4.5 months

  6. Physical function measured by Oxford Knee Scale

    Oxford Knee Scale

    Time frame: Preoperative, 6, 12 weeks and 4.5 months

  7. Range of motion: Physical function

    Time frame: Preoperative, 6, 12 weeks and 4.5 months

  8. Emotional function measured by GAD-7

    GAD-7

    Time frame: Preoperative, 6, 12 weeks and 4.5 months

  9. Emotional function measured by PHQ-9

    PHQ-9

    Time frame: Preoperative, 6, 12 weeks and 4.5 months

  10. Patient satisfaction

    Patient global impression of change (PGIC)

    Time frame: 1 week after start of intervention; 1, 6, and 12 weeks after surgery and 4.5 months after surgery

  11. Neuropathic pain

    Presence of neuropathic pain (S-LANSS)

    Time frame: 6 and 12 weeks post-surgery

  12. Chronic post-surgical pain

    Presence of chronic post-surgical pain (based on NRS \> 0)

    Time frame: 12 weeks post-surgery

  13. Quality of recovery (QoR-15)

    Change in Quality of Recovery-15 (QoR-15) score, a 15-item patient-reported questionnaire assessing postoperative recovery across pain, physical comfort, physical independence, psychological support, and emotional state.

    Time frame: 1/6/12 weeks and and 4.5 months post-surgery

  14. Adverse events

    Adverse events relating to study medication (dizziness, drowsiness, nausea, vomiting, insomnia)

    Time frame: 1 week after starting intervention; in hospital at POD1-3, and 1, 6, and 12 weeks post-op.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be available upon request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Upon publication, no limit on time

Access criteria: Contact study investigators

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 32 months after the start.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 32 months is above that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 21, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06423716
Responsible party
Dr. Howard Meng (Principal Investigator, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
May 21, 2024
Start date
Nov 1, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Howard Meng, MD
Contact
howard.meng@sunnybrook.ca
416-480-4864
Stephen Choi
Contact
stephen.choi@sunnybrook.ca
416-480 -4864

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duloxetine

Start the discussion